Acadia Pharma (ACAD) Misses Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results
May 7, 2020 4:07 PM EDT- 1Q20 Net Sales of $90.1 Million, a 43% Increase Over 1Q19
- On-track to submit supplemental NDA for pimavanserin for the treatment of dementia-related psychosis (DRP) this summer
- Announced worldwide license agreement and collaboration with Vanderbilt University for new central nervous system (CNS) therapeutic program
- 2020 revenue guidance reduced by approximately 5% due to currently anticipated COVID-19 impact
SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative... More
